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In this study, the effect of liposomal lipid composition on the physicochemical characteristics and adju-
vanticity of liposomes was investigated. Using a design of experiments (DoE) approach,
peptide-containing liposomes containing various lipids (EPC, DOPE, DOTAP and DC-Chol) and peptide
concentrations were formulated. Liposome size and zeta potential were determined for each formulation.
Moreover, the adjuvanticity of the liposomes was assessed in an in vitro dendritic cell (DC) model, by
quantifying the expression of DC maturation markers CD40, CD80, CD83 and CD86. The acquired data
of these liposome characteristics were successfully ﬁtted with regression models, and response contour
plots were generated for each response factor. These models were applied to predict a lipid composition
that resulted in a liposome with a target zeta potential. Subsequently, the expression of the DC matura-
tion factors for this lipid composition was predicted and tested in vitro; the acquired maturation
responses corresponded well with the predicted ones. These results show that a DoE approach can be
used to screen various lipids and lipid compositions, and to predict their impact on liposome size, charge
and adjuvanticity. Using such an approach may accelerate the formulation development of liposomal
vaccine adjuvants.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Many vaccines are based on puriﬁed or synthetic antigens
derived from their respective pathogens. These include antigens,
such as peptides and proteins, which are poorly immunogenic
on their own. Adjuvants, based on delivery systems and/or
immunopotentiators, are used frequently to improve the immuno-
genicity of antigens [1]. Liposomes are important delivery systems
for vaccines because of their high versatility, which enables them
to be suited for many types of antigens [2].
Numerous lipid compositions and preparation methods for lipo-
somes can be chosen, which affect several liposomal characteristics,
such as size, zeta potential, bilayer ﬂuidity and encapsulation or
association of antigen or adjuvant. In turn, these characteristics
can inﬂuence the adjuvant effect of liposomes [3]. The adjuvanticity
of liposomes is attributed to several mechanisms, such as antigendepot formation, induction of local inﬂammation and increased
antigen uptake by antigen presenting cells.
Antigen presenting cells, with dendritic cells (DCs) in particular,
play a pivotal role in the induction of adaptive immune responses.
DCs recognize, internalize and process antigens, and ultimately
present them to naïve CD4+ or CD8+ T cells [4]. The uptake of anti-
gens by DCs is affected by several antigen characteristics, of which
size and surface charge are the most inﬂuential. Generally, the size
of most subunit antigens is too small for the DC to be taken up efﬁ-
ciently. Incorporation of an antigen into a particulate delivery sys-
tem such as a liposome, whose size is comparable to that of a virus
particle, can therefore signiﬁcantly increase antigen uptake by DCs
through endocytosis [5].
The surface charge density of a liposome inﬂuences its zeta
potential, and thereby its electrostatic interaction with the surface
of a DC. Since cellular membranes are anionic, cationic liposomes
are ideally suited to increase antigen uptake by DCs [6]. It is gener-
ally accepted that anionic and neutral liposomes are less suited for
the induction of immune responses [7]. The cationic liposome for-
mulation CAF01 is currently advancing through clinical trials in
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potency of cationic liposomes [8,9].
For the successful priming of naïve B- or T cells by DCs, more is
needed than efﬁcient antigenuptake andprocessing. During antigen
presentationby theDCs tonaïve lymphocytes, costimulatory signals
are required. These are provided by the DCs, which can express cos-
timulatorymolecules such as CD40 (for B cells), CD80 and CD86 (for
T cells) aftermaturation [10]. Thematuration of DCs is considered to
be of vital importance for the overall immunogenicity of a vaccine
antigen [11]. In vitro DC maturation models can therefore be used
as preclinical screening tools for vaccine formulations [12].
Immunostimulatory signals, which are often provided by
pathogen-associated molecular patterns (PAMPs), are required
for the activation of DCs. Inclusion of PAMPs such as Toll-like
receptor (TLR) ligands or other molecules in liposomes is therefore
a popular strategy to increase liposome adjuvanticity [13,14].
Cationic lipids also seem to affect DC maturation [15]. Besides
the positive charge, other physical characteristics, such as lipid
bilayer ﬂuidity, may affect DC maturation [16]. Chemical differ-
ences between cationic lipids indeed have shown to affect DC mat-
uration, underlining the signiﬁcance of the lipid composition of
cationic liposomes.
Design of experiments (DoE) is a statistical method to screen,
identify and optimize important factors in various processes, suchFig. 1. Overview of the study concept. An experimental design describing liposomes w
software. Liposomes are formulated according to the design. Then, liposomes characteris
determined for each liposome formulation. Models are subsequently ﬁtted to the genera
liposomes with an untested lipid composition.as pharmaceutical formulation development [17,18]. It uses a min-
imal number of experiments to model the effects of each formula-
tion parameter, which signiﬁcantly accelerates the identiﬁcation of
optimal conditions. A DoE approach was recently employed to
optimize the formulation process of itraconazole-loaded liposomes
[19]. The authors were able to predict drug loading with a mathe-
matical model obtained with DoE, and identify critical formulation
parameters affecting drug loading. However, no attempts have
been made yet to predict biological parameters, such as the adju-
vanticity of liposomes, with DoE-like approaches.
In this study, the effects of liposomal lipid composition and pep-
tide incorporation on the physicochemical characteristics and the
adjuvanticity of liposomes were studied. To gain insight into the
effects of each component with a minimal number of experiments,
a DoE approach was used. The physicochemical characteristics of
the liposomes were determined as the liposome size and zeta
potential, while the liposome adjuvanticity was determined as
liposome-induced in vitro expression of DC maturation factors
CD40, CD80, CD83 and CD86. To this end, four lipids, i.e.,
egg-phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-pho
sphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) and 3ß-[N-(N0,N0-dimethylaminoethane)-
carbamoyl]cholesterol (DC-Chol), and the HLA-A2.1-restricted
inﬂuenza peptide GILGFVFTL (M158-66), were used to generateith various lipid compositions and peptide concentrations is generated with DoE
tics such as size, zeta potential and liposome-induced dendritic cell maturation are
ted data. Finally, these models can be used to predict the liposome characteristics of
Table 1
Design of experiments worksheet. Lipids (DOPE, DC-Chol, DOTAP, EPC) are presented as fraction of total lipid content (1 = 100%).
Formulation Run order Peptide (lg/mL) DOPE DC-Chol DOTAP EPC
N1 8 10 1 0 0 0
N2 13 10 1 0 0 0
N3 12 10 0 1 0 0
N4 18 10 0 0 1 0
N5 11 10 0 0 1 0
N6 9 10 0 0 0 1
N7 7 10 0 0.333333 0.333333 0.333333
N8 16 100 1 0 0 0
N9 17 100 0 1 0 0
N10 10 100 0 0 1 0
N11 6 100 0 0 0 1
N12 14 100 0.333333 0 0.333333 0.333333
N13 15 100 0.333333 0.333333 0 0.333333
N14 3 100 0.333333 0.333333 0.333333 0
N15 4 55 0.25 0.25 0.25 0.25
N16 1 55 0.25 0.25 0.25 0.25
N17 5 55 0.25 0.25 0.25 0.25
N18 2 55 0.25 0.25 0.25 0.25
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Liposome size and zeta potential were determined for each formu-
lation, and prediction models for these parameters were generated
by using a DoE approach. Simultaneously, the ability of these
liposomes to maturate DCs was evaluated by determining the
expression of DC maturation markers CD40, CD80, CD83 and
CD86. With DoE, the most inﬂuential lipids were identiﬁed, and
prediction models were generated for each maturation marker.
Finally, the prediction models were validated by selecting a lipo-
some with a previously untested lipid composition. A complete
overview of the study is depicted in Fig. 1.
2. Materials and methods
2.1. Reagents
The inﬂuenza peptide GILGFVFTL (M158-66) was synthesized at
the Dutch Cancer Institute (NKI). All lipids (EPC, DOPE, DOTAP,
DC-Chol) were purchased from Avanti Polar Lipids, bovine serum
albumin (BSA), ethylenediaminetetraacetic acid (EDTA), 4-(2-hyd
roxyethyl)-1-piperazineethanesulfonic acid (HEPES) and sodium
chloride from Sigma–Aldrich, Iscove’s Modiﬁed Dulbecco’s
Medium (IMDM) from Invitrogen, human granulocyte macrophage
colony-stimulating factor (GM-CSF) from Peprotech, human IL-4
from Sanquin, anti-human CD40-PE and CD80-FITC from BD
Pharmingen, anti-human CD83-APC and CD86-Paciﬁc Blue from
Biolegend, phosphate-buffered saline (PBS; 155 mM NaCl,
1.5 mM potassium phosphate monobasic, 2.7 mM sodium phos-
phate dibasic, pH 7.2) and live/dead-Aqua from Life Technologies,
lipopolysaccharide (LPS) E. coli K12 from Invivogen and Hyclone
fetal calf serum (FCS) from Thermo Scientiﬁc.Fig. 2. Liposome characteristics. (A) Size and polydispersity index (PDI) of
liposomes were determined by dynamic light scattering. (B) The zeta potential of
the liposomes was determined by laser Doppler velocimetry. Data are presented as
mean ± upper/lower values, n = 2.2.2. Experimental design
To investigate the effect of the liposome composition on lipo-
some size, zeta potential and liposome-induced DC maturation, a
linear mixture model was selected with MODDE 10 (Umetrics)
software. Boundaries for EPC, DOPE, DOTAP and DC-Chol fractions
were set at 0 and 1 (with 1 being 100% of total lipid content).
GILGFVFTL peptide content was set between 10 and 100 lg/mL.
A D-optimal design was selected, which was composed of 18 runs,
including a quadruple center point [20]. After the runs were
completed, models for liposome zeta potential and DC maturation
factors CD40, CD80, CD83 and CD86 were created with apartial-least square (PLS) regression. Data were log-transformed,
if needed, and non-signiﬁcant factors were removed from the
model until R2 (model ﬁt) and Q2 (model prediction power) were
optimal.2.3. Liposome formulation
Lipids were admixed (ratios according to the experimental
design) to a total amount of 7.5 lmol in 10 ml chloroform. The lipid
mixture was transferred to a 50 mL round bottom ﬂask, and the
chloroform was evaporated under reduced pressure at 40 C with
a rotary evaporator (Buchi Rotavapor R-3). The obtained lipid ﬁlm
was subsequently rehydrated for 2 h, room temperature at
Fig. 3. Regression models for liposome size (A) and zeta potential (B). On the left summaries of ﬁt for the models are displayed. Model ﬁt (R2, >0.5 indicates a good model ﬁt to
the data), prediction power (Q2, >0.5 indicates sufﬁcient prediction power), model validity (>0.25 indicates that the model error is smaller than the experimental error) and
reproducibility (>0.5 indicates a small experimental error) are shown. On the right, normalized model regression coefﬁcients are displayed. Coefﬁcients with a 95% conﬁdence
interval that does not cross zero are signiﬁcant terms.
Fig. 4. Response contour plots for liposome size and charge. Lipid amounts are displayed as a fraction of 100% total lipid. The fraction of the least inﬂuential lipid was set at a
constant fraction of 0.25. The values in the boxes and associated color regions represent the predicted response (either size (nm) or zeta potential (mV)) for that particular
lipid composition.
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of GILGFVFTL peptide (concentrations according to experimental
design) dissolved in 1.5 mL buffer (10 mM HEPES, 100 mM NaCl,
pH7.4). After rehydration, crude liposomeswereextrudedﬁve times
through a 0.2-lm Nucleopore Track-Etch membrane (Whatman)
with a 10-mL Lipex extruder (Northern Lipids Inc.). Each liposome
formulation from the experimental design was made in duplicate.2.4. Characterization of liposomes
Liposome size and polydispersity index (PDI) were determined
by dynamic light scattering (DLS) using a Nanosizer ZS (Malvern
Instruments). The zeta potential of the liposomes was determined
after a 5 fold dilution in MilliQ water by laser Doppler velocimetry
usingaNanosizer ZSwith auniversal dip cell (Malvern Instruments).
Fig. 5. Dendritic cell maturation marker expression after stimulation with either medium or liposomes. Maturation markers are expressed as % mean ﬂuorescent intensity
(MFI) relative to that induced by LPS (MFILPS). Data represent mean + upper value, n = 2.
P.C. Soema et al. / European Journal of Pharmaceutics and Biopharmaceutics 94 (2015) 427–435 4312.5. Maturation of human dendritic cells
Human CD14+ monocytes were isolated from fresh donor blood
as described previously [21]. Monocytes were plated at a concen-
tration of 0.4 ⁄ 106 cells/mL in 24-wells plates in IMDM medium
containing 1% FCS, 500 U/mL GM-CSF and 800 U/mL IL-4.
Monocytes were differentiated to immature dendritic cells (iDCs)
after 6 days. iDCs were subsequently stimulated with either med-
ium, LPS or liposomes in duplicate. After 24 h incubation, cells
were transferred to a 96-wells plate and washed twice with FACS
buffer (PBS, pH 7.2, 0.5% BSA, 0.5 mM EDTA). DCs were stained
with anti-human CD40, CD80, CD83, CD86 and live/dead staining
for 30 min, and subsequently washed twice with FACS buffer.
Samples were measured on a FACS Canto II ﬂow cytometer (BD).
Data were analyzed by using FlowJo 10 software for Mac OSX
(Tree Star Inc.). Surface markers are reported as % of mean ﬂuores-
cent intensity (MFI) relative to that induced by LPS.3. Results
3.1. Liposome characteristics
A linear mixture model was selected to screen the effects of the
lipids EPC, DOPE, DC-Chol and DOTAP on the size distribution and
zeta potential of the liposomes and their ability to induce DC mat-
uration. A D-optimal design was chosen, which generated a work-
sheet with 18 formulations (Table 1). Physical characteristics of the
liposomes, i.e., size, PDI and zeta potential, were determined.
Formulations N1, N2 and N8, which all contained DOPE as the only
lipid, did not yield liposomes and were excluded from further
experiments. Liposome sizes ranged from 150 to 194 nm, with an
average of 170 nm (Fig. 2A) and a low PDI (<0.2), indicating that
the liposomes were relatively monodisperse. As expected, the zeta
potential of the liposomes containing a cationic lipid (DOTAP
and/or DC-Chol) was positive, whereas formulations lacking a
cationic lipid (N6, N11) showed a zeta potential close to zero
(Fig. 2B).
Based on the experimental results, PLS regression models were
ﬁtted for both liposome size and zeta potential data using MODDE
software. These regression models allowed the identiﬁcation and
qualiﬁcation of input parameters (being peptide, DOPE, DC-Chol,
DOTAP and EPC) which signiﬁcantly contributed to the output
parameters (size and zeta potential). The model regression coefﬁ-
cients reﬂect the inﬂuence of the particular input parameter on
the response of the output parameter. Valid models were obtained
for both output parameters (Fig. 3). Liposome size was inﬂuenced
the most by EPC (Fig. 3A), which increased liposome size when pre-
sent in high amounts. Model validity for the zeta potential model
was low (a value > 0.25 indicates a good model ﬁt), which is likelya model artifact caused by the high reproducibility [20]. DOTAP
and EPC were the most signiﬁcant model terms, with DOTAP
increasing the zeta potential, and EPC decreasing it (Fig. 3B). The
incorporation of the peptide antigen had no inﬂuence on both lipo-
some size and zeta potential, and was thus removed as a model
term.
Response contour surface plots were generated for both
liposome size and zeta potential after the ﬁtting of the regression
models (Fig. 4). These surface plots visualize the predicted value
of a response factor according to the corresponding lipid composi-
tion at that speciﬁc position in the plot (due to the
two-dimensional nature of these plots and the multi-dimensional
nature of the regression models, one input parameter is kept con-
stant). As expected, both cationic lipids (DOTAP and DC-Chol)
increased to zeta potential of the liposomes, whereas the zwitteri-
onic lipids (EPC and DOPE) decreased it.3.2. DC maturation by liposomes
The effect of the liposomal lipid composition on DC maturation
was evaluated by measuring four DC maturation markers (CD40,
CD80, CD83 and CD86) on maturated DCs 24 h after stimulation
with the liposome formulations from the experimental design.
The formulations were tested in duplicate on immature DCs iso-
lated from two different donors (donors 1 and 2). LPS was taken
as a positive control and reference sample in both experiments.
The expression of CD40, CD80, CD83 and CD86 by DCs (derived
from donor 1) after stimulation with the liposomes is presented
in Fig. 5.
Datasets from both experiments were ﬁtted with PLS regression
models per individual maturation marker, and the resulting mod-
els and their coefﬁcients are summarized in Fig. 6 (maturation
experiment on DCs derived from donor 1) and Supplementary
Fig. S1 (maturation experiment on DCs derived from donor 2).
While the resulting models differed between experiments (most
likely due to donor variability), the models showed similar trends.
Since this study concerned a proof-of-principle, we opted to inves-
tigate the models obtained with DCs derived from donor 1 in more
detail, since overall ﬁt of the models from donor 1 were better than
those of donor 2.
For both CD40 and CD80 responses models were yielded with a
high model ﬁt, validity and reproducibility. Formulation N14 was
statistically found to be an outlier, and was subsequently removed
from all models. For both CD40 and CD80, the DOTAP lipid was
found to be the most signiﬁcant model term, indicating that the
presence of DOTAP in the liposomes induces CD40 and CD80
expression by DCs. The model for CD83 had a relatively low model
validity, which again might be a model artifact caused by the high
reproducibility. The two cationic lipids, DC-Chol and DOTAP, were
Fig. 6. Regression models for dendritic cell maturation markers CD40 (A), CD80 (B), CD83 (C) and CD86 (D). On the left summaries of ﬁt for all models are displayed. Model ﬁt
(R2, >0.5 indicates a good model ﬁt to the data), prediction power (Q2, >0.5 indicates sufﬁcient prediction power), model validity (>0.25 indicates that the model error is
smaller than the experimental error) and reproducibility (>0.5 indicates a small experimental error) are shown. The normalized model regression coefﬁcients are displayed on
the right. Coefﬁcients with a 95% conﬁdence interval that does not cross zero are signiﬁcant terms.
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was valid, but suffered overall from a relatively low model ﬁt, pre-
dictability and reproducibility. This was conﬁrmed with the model
coefﬁcients, which all have a non-signiﬁcant contribution to the
CD86 response, indicating that no single lipid had a great effect.
Similar to the models for liposome size and zeta potential, the pep-
tide content was a non-signiﬁcant model term in all the models for
the maturation markers. The response contour surface plots of all
four maturation markers are displayed in Fig. 7. From these ﬁgures
it can be clearly seen that in general, a high fraction of DOTAP andto a lesser extent DC-Chol, has a positive effect on the expression of
all maturation markers. Furthermore, the inclusion of DOPE gener-
ally had a negative effect on the maturation. The lipid EPC was
non-inﬂuential for most responses, and is therefore still suited as
a helper lipid to produce stable liposomes.
3.3. Prediction power of obtained models
As described previously, valid prediction models were obtained
for liposomal size, zeta potential and all four DC maturation
Fig. 7. Response contour plots for DC maturation markers induced by liposomes. Lipid amounts are displayed as a fraction of 100% total lipid. The fraction of the least
inﬂuential lipid was set at a constant fraction of 0.25. The values in the boxes and associated color regions represent the predicted response (either CD40, CD80, CD83 or CD86,
all in % of LPS-induced expression) for that particular lipid composition.
Table 2
Lipid composition of a liposome formulation predicted to have a zeta potential of
30 mV by the zeta potential model.
Formulation Peptide (lg/mL) DOPE DC-Chol DOTAP EPC
N19 13.4 0.03 0.07 0.13 0.77
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ing a liposomal formulation that was not yet included in the
D-optimal design. For proof-of-principle purposes, an initial target
response factor was set for the liposome formulation. In this case, atarget liposomal zeta potential was set. Since most formulations in
the experimental design showed a zeta potential of either above
60 mV or 0 mV, a target zeta potential of 30 mV was chosen. The
zeta potential prediction model subsequently gave a lipid compo-
sition (Table 2) which should yield liposomes with a zeta potential
of 30 mV. The liposome formulation (N19) was made, and size and
zeta potential were determined (Table 3), which indeed correlated
with the predicted values. Subsequently, the selected lipid compo-
sition could now be used as an input for the previously acquired
prediction models for liposomal adjuvanticity.
Next, liposome formulation N19 was added to immature DCs,
and DC maturation markers were determined. The experimentally
Table 3
Assessment of the validity of the prediction models. The liposome size, zeta potential
and liposome-induced maturation markers were predicted by the acquired models for
formulation N19. Prediction is expressed as mean ± 95% conﬁdence intervals.
Measured values are given as mean ± upper/lower values, n = 2.
Predicted mean Lower Upper Measured
Size (nm) 188.5 183.3 193.7 181.1 ± 8.7
PDI n.a.a n.a. n.a. 0.12 ± 0.01
Zeta potential (mV) 30.0 17.1 39.5 30.3 ± 6.2
CD40 (% MFILPS) 52.3 40.1 64.5 46.2 ± 16.8
CD80 (% MFILPS) 32.9 30.9 34.7 31.1 ± 3.9
CD83 (% MFILPS) 13.1 9.6 17.7 13.0 ± 4.0
CD86 (% MFILPS) 24.8 19.7 29.8 26.1 ± 6.8
a Not applicable; no valid prediction model for PDI was generated in this study.
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cating that the predictions made by the models were accurate.4. Discussion
From a historical perspective, most researchers are inclined to
vary one factor at a time (OFAT) when systematically screening
or optimizing a certain system or formulation. Such OFAT
approaches however are ineffective, since the number of experi-
ments increases exponentially when a variable is added to the
design. Another drawback of OFAT is that important interactions
between the parameters can be missed. Utilizing a DoE approach
instead solves some of these OFAT-associated constraints, by
decreasing the number of experiments needed to screen multiple
variables, and to visualize interactions with the aid of statistical
models. Furthermore, prediction models can be generated from
the existing data, which can predict inter- or extrapolated variables
that have not been tested yet.
In the current study, a DoE approach was used to investigate a
ﬁve-component (one antigen and four lipids) liposomal system
with respect to physicochemical properties and biological activity:
size, zeta potential and liposome-induced DC maturation. While
DoE approaches are increasingly used for the formulation and pro-
cess development of pharmaceuticals [4], they have been rarely
used in studies involving liposomes. Two previous studies investi-
gated the role of different liposome formulation processes on the
encapsulation efﬁciency of either a poorly soluble drug molecule
[19], itraconazole, or a small peptide [22]. These studies proved
that the DoE approach is applicable for the development and opti-
mization of liposomal formulations. In this current study, it was
found that the liposomal lipid composition affected liposomal
characteristics such as size, zeta potential and liposome-induced
DC maturation. The inclusion of a peptide antigen, however, was
not of inﬂuence on any of these factors.
It is clear from our results that the liposomal lipid composition
inﬂuenced the expression of DC maturation markers. However,
not much is yet known on the individual effects of these lipids
on expression of CD40, CD80, CD83 or CD86. Vangasseri et al. pre-
viously demonstrated that liposomes containing DOTAP effec-
tively induced CD80 and CD86 expression by DC2.4 cells [16].
When the cationic head group of DOTAP was replaced by anionic
or neutral head groups, the liposomes lost their ability to induce
DC maturation. Similarly, replacement of the unsaturated fatty
acid chain of DOTAP with saturated analogues was detrimental
to the maturation response. Addition of counter ions to the
cationic liposomes also did not affect their ability to induce DC
maturation. Another study showed similar results with
DOTAP:DOPC liposomes; a higher molar ratio of DOTAP
correlated with increased CD83 and CD86 expression by human
monocyte-derived DCs [23]. From these results, it washypothesized that not only the zeta potential of the liposomes,
but also the chemical composition of the lipids inﬂuenced the
immunostimulatory properties of liposomes.
Our results conﬁrm that liposomes containing cationic lipids,
particularly DOTAP, were able to induce DC maturation.
Contrarily to the expression of CD80, CD86 and CD40, the CD86
marker expression was more sensitive to DC-Chol than to
DOTAP. It has been previously reported that DC-Chol liposomes
also have an immunostimulatory effect on DCs [15]. The difference
in expression of the maturation markers with these two cationic
lipids might be related to the chemical and structural differences
between the lipids, as mentioned earlier. Further studies are
needed to elucidate the underlying mechanisms for these differ-
ences, in order to support the rational design of optimal cationic
liposomes for the induction of DC maturation and subsequent
immune responses.
The maturation experiments in the current study were per-
formed on immature DCs derived from human blood monocytes
isolated from donors. This introduces a donor variety into the DC
studies, which can have a large effect on the prediction models.
Indeed, the obtained prediction models from experiments using
two differed iDC donor sources showed some differences due to
biological donor variety. To eliminate this biological variability
from the models, future investigations could be performed on
immortalized DC cell lines. Human-derived DC cell lines such
as MUTZ-3 have been used to screen vaccine immunogenicity,
and showed consistent maturation responses opposed to monocyte-
derived DCs from fresh blood, which showed a large donor variabil-
ity [24]. Using such cell lines would probably yield prediction mod-
els that can be used continually on the same cell line, which is a
huge advantage for the reproduction of the experiments. When
combined, the current DoE approach and established DC cell lines
could form an effective platform to rapidly screen liposomal
(and other) vaccine formulations without the use of animal studies
[12].
Aside from the liposome-induced DC maturation responses, the
effects of lipid composition on liposome size and zeta potential
were investigated and modeled. While the size of the liposomes
is mostly dictated by the formulation method (e.g., extrusion and
sonication), the lipid composition does inﬂuence the size to some
extent. This may be accredited to differences in lipid tail length,
molecular shape and membrane ﬂuidity, but also the incorporation
of charged lipids. Nonetheless, the size variations observed in this
study were small, and therefore most likely did not inﬂuence
size-dependent mechanisms, such as uptake by DCs [25]. The zeta
potential of the liposomes was inﬂuenced by the lipid composition.
The cationic lipids DC-Chol and DOTAP both increased the zeta
potential of the liposomes, while EPC had a neutralizing effect on
the zeta potential. The acquired model for zeta potential could
accurately predict a suitable lipid composition of a liposome with
a zeta potential of 30 mV. The ability to predict the zeta potential
of a liposome according to its lipid composition could be a power-
ful tool, since the zeta potential of liposomes affects several factors
[26], such as their colloidal stability (electrostatic repulsion),
encapsulation efﬁciency of a drug or antigen (electrostatic attrac-
tion) and depot formation at the injection site.
In conclusion, this study shows the usefulness of a DoE
approach to investigate the inﬂuence of the lipid composition
and antigen content of liposomes on their physicochemical charac-
teristics (size and zeta potential) and biological effect (maturation
of DCs). The obtained models were able to accurately predict lipo-
some size, zeta potential, and relative levels of liposome-induced
DC maturation factors CD40, CD80, CD83 and CD86. This approach
could be a valuable method for the development of
liposome-based vaccine adjuvants.
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